4.2 Article

Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score

期刊

PHARMACOGENOMICS
卷 16, 期 11, 页码 1275-1284

出版社

FUTURE MEDICINE LTD
DOI: 10.2217/pgs.15.70

关键词

capecitabine; dihydropyrimidine dehydrogenase; DPYD; 5-fluorouracil; fluoropyrimidines; gene activity score; individualized medicine; pharmacogenomics

资金

  1. Dutch Cancer Society
  2. Roche Pharmaceuticals

向作者/读者索取更多资源

The dihydropyrimidine dehydrogenase enzyme (DPD, encoded by the gene DPYD) plays a key role in the metabolism of fluoropyrimidines. DPD deficiency occurs in 4-5% of the population and is associated with severe fluoropyrimidine-related toxicity. Several SNPs in DPYD have been described that lead to absent or reduced enzyme activity, including DPYD*2A, DPYD*13, c.2846A>T and c.1236G>A/haplotype B3. Since these SNPs differ in their effect on DPD enzyme activity, a differentiated dose adaption is recommended. We propose the gene activity score for translating DPYD genotype into phenotype, accounting for differences in functionality of SNPs. This method can be used to standardize individualized fluoropyrimidine dose adjustments, resulting in optimal safety and effectiveness.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据